April 24, 2008-Strides Arcolab today announced receipt of 2 ANDA approvals for Ondansetron Injection USP, 2 mg/ml (20 ml vials) and 2 mg/ml (2 ml vials).
The product is licensed to Akorn-Strides, LLC, which is a Joint Venture that was formed in 2004 by Akorn, Inc and Strides Arcolab Limited.
Mr.Arun Kumar - Vice Chairman and Group CEO of Strides Arcolab stated:
"These approvals reflect yet another significant milestone for the Akorn-Strides partnership which now has approvals for five sterile injectable products and plans for commercialization are underway. "
No comments:
Post a Comment